Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduction of monoclonal antibody-based biosimilars, aiming to reduce the cost-burden of originator antibody therapies. The tailored approach used by manufacturers to improve the targeting efficiency of drug molecules toward multiple antigens is strengthening the pipeline portfolio of SMEs in the antibodies space and accelerating the pace of antibody drug development for cancer treatment.
Immuno-oncology remains a key focus area in the antibody therapeutics market, especially due to the emergence of highly target-specific antibody-drug conjugates and bispecific antibodies. Key manufacturers are striving to reduce in-house operations to leverage the capabilities of contract development and manufacturing organizations (CDMOs) with the aim of boosting innovation in the industry, which is likely to change the face of the market over the next 5 years.
Research Scope
This Frost & Sullivan research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities. As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space. Moreover, adoption of the antibody drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.
Research Highlights
- Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027
- Dynamics around product innovation and the reimbursement scenario
- Regulatory reforms and technological advancements driving value chain transformation
- Current and future R&D efforts and investment outlook
- Growth opportunities that market participants can focus on in the near future
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Antibody Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Scope of Analysis
Segmentation and Definition
Definitions by Technology Subtype
Growth Drivers
Growth Restraints
Key Takeaways
Antibody Therapeutics—Pipeline Snapshot
Pipeline Scenario of Late-stage Antibody Therapeutics
Potential Therapy Areas
Value Chain—Key Stakeholders
Key Antibody Therapeutics Manufacturers
Key Industry Trends by Region
Key Industry Trends by Region (continued)
Key Industry Trends by Route of Administration
Key Industry Trends—Antibody-Drug Conjugates
Key Industry Trends—Technological Advancements
Pricing Analysis of Antibody Therapeutics
Factors Influencing the Pricing of Antibody Therapeutics
Reimbursement Scenario for Antibody Therapeutics
Reimbursement for Antibody Therapeutics—Regional Overview
Notable Partnerships and Collaborations for Antibody Therapeutics
Notable Partnerships and Collaborations for Antibody Therapeutics (continued)
Growth Metrics
Research Methodology
Forecast Assumptions
Revenue Forecast
Revenue Forecast Analysis
Revenue Forecast by Technology
Revenue Forecast by Technology Discussion
Competitive Environment
Revenue Share Analysis
Key ADC Developers to Watch in 2022
Growth Opportunity 1—Developing Multi-specific Antibodies for Immuno-oncology
Growth Opportunity 1—Developing Multi-specific Antibodies for Immuno-oncology (continued)
Growth Opportunity 2—Collaborating with CDMOs and Platform Providers for the Further Development of ADCs
Growth Opportunity 2—Collaborating with CDMOs and Platform Providers for the Further Development of ADCs (continued)
Key Alliances in ADCs
Growth Opportunity 3—Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars
Growth Opportunity 3—Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars (continued)
List of Exhibits
Legal Disclaimer
List of Figures- Antibody Therapeutics: Growth Drivers, Global, 2022 2027
- Antibody Therapeutics: Growth Restraints, Global, 2022 2027
- Clinical Pipeline of Antibody Therapeutics: By Therapy Area, Global, 2021
- Late stage Clinical Pipeline of Antibody Therapeutics: By Therapy Area, Global, 2021
- Major Late stage Pipeline of Antibody Therapeutics for Cancer, Global, 2021
- Major Late stage Pipeline of Antibody Therapeutics for Non cancer Indications, Global, 2021
- Antibody Therapeutics: Value Chain Key Stakeholders, Global, 2021
- Antibody Therapeutics: Proportion of Approved Antibody Therapeutics (by Route of Administration), Global, 2021
- Antibody Therapeutics: Average Annual Price of Antibody Therapeutics per Patient (by Therapy Area), Global, 2021
- Antibody Therapeutics: Growth Metrics, Global, 2021 2027
- Antibody Therapeutics: Revenue Forecast, Global, 2021 2027
- Antibody Therapeutics: Revenue Forecast by Technology, Global, 2021 2027
- Antibody Therapeutics: Percent of Revenue by Technology, Global, 2021 2027
- Antibody Therapeutics: Competitive Environment, Global, 2021
- Antibody Therapeutics: Market Share of Top Participants, Global, 2021
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Research Scope
This Frost & Sullivan research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities. As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space. Moreover, adoption of the antibody drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.
Research Highlights
- Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027
- Dynamics around product innovation and the reimbursement scenario
- Regulatory reforms and technological advancements driving value chain transformation
- Current and future R&D efforts and investment outlook
- Growth opportunities that market participants can focus on in the near future
| Deliverable Type | Market Research |
|---|---|
| Author | Mrinal Kerhalkar |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | antibody therapeutics market |
| Keyword 2 | Monoclonal Antibody Therapeutics Market |
| Keyword 3 | Monoclonal Antibodies Market |
| List of Charts and Figures | Antibody Therapeutics: Growth Drivers, Global, 2022 2027~ Antibody Therapeutics: Growth Restraints, Global, 2022 2027~ Clinical Pipeline of Antibody Therapeutics: By Therapy Area, Global, 2021~ Late stage Clinical Pipeline of Antibody Therapeutics: By Therapy Area, Global, 2021~ Major Late stage Pipeline of Antibody Therapeutics for Cancer, Global, 2021~ Major Late stage Pipeline of Antibody Therapeutics for Non cancer Indications, Global, 2021~ Antibody Therapeutics: Value Chain Key Stakeholders, Global, 2021~ Antibody Therapeutics: Proportion of Approved Antibody Therapeutics (by Route of Administration), Global, 2021~ Antibody Therapeutics: Average Annual Price of Antibody Therapeutics per Patient (by Therapy Area), Global, 2021~ Antibody Therapeutics: Growth Metrics, Global, 2021 2027~ Antibody Therapeutics: Revenue Forecast, Global, 2021 2027~ Antibody Therapeutics: Revenue Forecast by Technology, Global, 2021 2027~ Antibody Therapeutics: Percent of Revenue by Technology, Global, 2021 2027~ Antibody Therapeutics: Competitive Environment, Global, 2021~ Antibody Therapeutics: Market Share of Top Participants, Global, 2021~ |
| Podcast | No |
| WIP Number | PD66-01-00-00-00 |
Global Antibody Therapeutics Growth Opportunities
The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth
19-Aug-2022
North America
Market Research